RESUMEN
Cardiac dysfunction is a common and severe side-effect after cancer therapy including thoracic radiation or cytotoxic agents. With the development of the cancer therapy method and the agents, the survival time of the patients has improved while most cancer patients could live with tumor or even be cured. The rate of cancer therapeutics-related cardiac dysfunction have obviously increased which seriously affect the time and life quality of patients with tumor. But there are no authoritative consensus criteria or guideline to diagnose CTRCD at present while it is difficult to identify CTRCD with primary heart disease. In this article，we summarized some diagnosis methods which could identify early CTRCD，and then we may give early drug intervention as soon as possible to reduce the incidence and remission rate of cardiovascular events.